These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 34780673)
1. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas. Liu Y; Liu S; Li G; Li Y; Chen L; Feng J; Yang Y; Jiang T; Qiu X Cancer; 2022 Mar; 128(5):1085-1092. PubMed ID: 34780673 [TBL] [Abstract][Full Text] [Related]
2. High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase. Liu Y; Li Y; Wang P; Chen L; Feng J; Qiu X Radiat Oncol; 2021 Aug; 16(1):157. PubMed ID: 34412650 [TBL] [Abstract][Full Text] [Related]
3. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas. Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640 [TBL] [Abstract][Full Text] [Related]
5. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas. Yang X; Lin Y; Xing Z; She D; Su Y; Cao D Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488 [TBL] [Abstract][Full Text] [Related]
6. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation. Khurana R; Rath S; Singh HB; Rastogi M; Nanda SS; Chauhan A; Kaif M; Hussain N Asian Pac J Cancer Prev; 2020 Mar; 21(3):755-760. PubMed ID: 32212804 [TBL] [Abstract][Full Text] [Related]
7. The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT). Zhong Q; Luo D; Chen D; Li X; Du Q; Liang Q; Li J; Zhu X Aging (Albany NY); 2023 Aug; 15(15):7781-7793. PubMed ID: 37556350 [TBL] [Abstract][Full Text] [Related]
9. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
10. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545 [TBL] [Abstract][Full Text] [Related]
11. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas. Liu Y; Chen H; Li G; Zhang J; Yao K; Wu C; Li S; Qiu X Cancer Biol Med; 2022 Nov; 19(10):1477-86. PubMed ID: 36350001 [TBL] [Abstract][Full Text] [Related]
12. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469 [TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
14. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]